English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Meloxicam, a non-steroidal anti-inflammatory drug acting on the principle of cyclooxygenase-2 inhibition and having an improved side-effect profile in terms of the gastrointestinal toxicity, has been found to stimulate hematopoiesis in whole-body sub-lethally or mid-lethally gamma-irradiated mice. Studies on mechanisms of the hematopoiesis-stimulating action of meloxicam have revealed elevated serum levels of granulocyte colony-stimulating factor (G-CSF) within the interval of 24 hours after the administration of the drug. Induction of production of G-CSF may be, thus, supposed to be at least partially responsible for the observed beneficial effects of meloxicam in mice with radiation-induced myelosuppression. This work was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (Grant No. 1QS500040507).

Meloxicam, a Cyclooxygenase-2 Inhibitor, Stimulates Myelopoiesis in Irradiated Mice Via Induction of G-CSF